Thalidomide-O-amido-C6-NH2 hydrochloride

Background Introduction

Thalidomide-O-amido-C6-NH2 hydrochloride is a premium E3 ligase ligand-linker conjugate designed for use in targeted protein degradation technology, most notably in PROTAC (Proteolysis Targeting Chimera) research and development. This compound combines a thalidomide-based cereblon (CRBN) ligand with a hexyl (C6) amide linker terminated with an amine group, offering high versatility for the synthesis of bifunctional molecules. With its optimized structure, Thalidomide-O-amido-C6-NH2 hydrochloride enables researchers to efficiently generate PROTACs for preclinical and drug discovery applications.

Mechanism

Thalidomide-O-amido-C6-NH2 hydrochloride functions as a modular building block in PROTAC synthesis. The thalidomide moiety serves as a high-affinity ligand for the E3 ubiquitin ligase cereblon (CRBN), a key component responsible for tagging target proteins with ubiquitin for proteasomal degradation. The C6 amido linker provides flexible spatial orientation, while the terminal amine allows for straightforward conjugation via amide coupling or other bioconjugation strategies to a wide array of protein-targeting ligands. When fashioned into a PROTAC, this conjugate bridges the E3 ligase and the target protein, resulting in selective ubiquitination and degradation of the target protein within the cell.

Applications

Thalidomide-O-amido-C6-NH2 hydrochloride is widely used in the design and synthesis of PROTACs, molecular glues, and other heterobifunctional molecules. Its optimized structure enhances the development of chemical probes for protein function study and accelerates the discovery of novel therapeutics by enabling targeted protein degradation. This compound is particularly valuable in oncology, neurodegenerative disease, and immunology research, where precise protein knockdown is critical for understanding disease mechanisms and discovering next-generation therapeutics. Compatible with standard solid- and solution-phase synthetic techniques, it supports efficient library generation and rapid lead optimization in drug discovery programs.

Thalidomide-O-amido-C6-NH2 hydrochloride is a versatile E3 Ligase Ligand-Linker Conjugate used in the development of PROTACs for targeted protein degradation. It combines a potent E3 ligase ligand with a strategically designed linker, facilitating efficient degradation of disease-related proteins. The following provides a detailed description of this molecule.

Linker: The linker in this molecule is a C6 alkyl chain, providing moderate length and flexibility, which is crucial for effective spatial orientation between the ligand and the target protein. Its non-cleavable nature ensures stability and sustained interaction within the cellular environment.

Ligand: The ligand component is derived from thalidomide, known for its high affinity binding to the cereblon E3 ubiquitin ligase. Its phthalimide moiety is crucial for the recruitment of the ubiquitin-proteasome system, enhancing the degradation efficiency of the target protein.

Reactive Site: The reactive site features an amido group that couples efficiently with primary amine groups on the target protein ligand. Recommended reaction types include amide bond formation through carbodiimide-mediated coupling, ensuring a stable and robust conjugation.

Recommended Target Protein Ligand: The recommended warhead for this conjugate is a small molecule with a primary amine group, providing ease of conjugation through amide bond formation. This setup is advantageous for creating PROTACs aimed at degrading kinases or transcription factors, offering a strategic approach to modulate protein levels in cellular models for research purposes.